Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.
Prostate Cancer
DRUG: Docetaxel|DRUG: Estramustine
Response Rate
Rate of recurrence|Toxicity
Upon determination of eligibility, patients will receive:

Docetaxel + Estramustine